Manufacturers lobby US Congress for assistance to develop orphan products
This article was originally published in Clinica
The US Medical Device Manufacturers Association (MDMA) last week called for legislation to speed up the development of medical devices for diagnosing and treating rare disorders. The concept is similar to the 1983 Orphan Drug Act that has successfully led to advances in pharmaceutical treatments for rare diseases.
You may also be interested in...
Italy Round-Up: Mylan And Polifarma Strike Deal, OTC Market Stable, Cholesterol-Lowering Probiotic Launch
The latest news from Italy's OTC and supplements markets, including the latest sales figures, business deals, product launches, ad regulation and local association activities.
Sandoz CEO Richard Saynor has pledged that the company will ensure stable pricing for essential coronavirus-related medicines amid concerns over how the outbreak will affect the supply chain.
Executives On The Move: Comings And Goings At Atara Biothera And Pfizer, Along With A Promotion At Domainex
T-cell immunotherapy firm Atara Biotherapeutics decides on a chief commercial officer and Pfizer oncology R&D head leaves for CSO spot at Vividion Therapeutics. Also, COO of UK drug discovery CRO Domainex is set to climb to CEO position.